ZTlido Patch for Post-Shingles Pain Launching Soon

This article originally appeared here.
Share this content:
ZTlido will be available as 1.8% patches in 30-count cartons.
ZTlido will be available as 1.8% patches in 30-count cartons.

Scilex, a subsidiary of Sorrento, announced that ZTlido (lidocaine topical system) 1.8% patches are anticipated to launch in October 2018. 

ZTlido is a topical agent that was approved in February 2018 for the relief of pain associated with post-herpetic neuralgia (PHN), or post-shingles pain. The non-aqueous adhesive patch requires 36mg per topical system to achieve the same therapeutic dose as Lidoderm (lidocaine 5%) which contains 700mg per patch. A Phase 1 adhesion study (n=44) also showed superior adhesion with ZTlido vs Lidoderm at 3 hours (P<0.0001) with improvements seen over the 12-hour period. 

Lidocaine is a topical local anesthetic that blocks sodium ion channels required for the initiation and conduction of neuronal impulses. 

George Ng, President, Business, of Scilex, stated, "With ZTlido, we are proud to offer a non-opioid alternative and option for patients with post-herpetic neuralgia.”

ZTlido will be available as 1.8% patches in 30-count cartons. 

Follow @ClinicalPainAdv

For more information call (858) 203-4100 or visit ZTlido.com.

You must be a registered member of Clinical Pain Advisor to post a comment.